Discrimination between urosepsis and febrile urinary tract infections is important in therapeutic decision-making to indicate suitable treatments to avoid sepsis-related organ failure. Accurate diagnosis is time-consuming and susceptible to false-positive results. Moreover, patient responses to urosepsis are complex and varied. Therefore, this study aimed to develop a new, early diagnostic predictor that could discriminate between patients with urosepsis and those with febrile urinary tract infections using a combination of initial procalcitonin and albumin levels.We conducted a retrospective study involving 140 patients with febrile urinary tract infections from January 2013 to December 2017. Univariate and multivariate logistic analyses were performed to identify the independent risk factors for differentiating urosepsis from febrile urinary tract infection. A receiver operating characteristic (ROC) curve analysis was conducted to compare the predictive accuracy of the procalcitonin/albumin ratio.Patients in the urosepsis group had higher procalcitonin/albumin ratios compared to those in the febrile urinary tract infection group [2.254 (0.978, 6.299) vs 0.021 (0.004, 0.095); P < .001]. Based on multivariate logistic analysis, the procalcitonin/albumin ratio [adjusted odds ratio (OR) 1.029, 95% confidence interval (CI) 1.013-1.045, P < .001] was an independent predictor of urosepsis, which allowed for differentiation from patients with febrile urinary tract infections. The area under the ROC curve (AUC) for the procalcitonin/albumin ratio was 0.937 (95% CI, 0.894-0.980); P < .001. The sensitivity and specificity of the procalcitonin/albumin ratio cut-off values (>0.44) were 84.62% and 96.00%, respectively. Moreover, in the subset of 65 patients with urosepsis, the procalcitonin/albumin ratio in the uroseptic shock group was higher than in the group of patients without uroseptic shock [5.46 (1.43, 6.58) vs 1.24 (0.63, 4.38); P = .009].Our study demonstrates that the procalcitonin/albumin ratio is an early diagnostic predictor that can discriminate between urosepsis and febrile urinary tract infection. Additionally, in patients with urosepsis, those with higher procalcitonin/albumin ratios were more prone to uroseptic shock. Our findings suggest that the procalcitonin/albumin ratio is a rapid and relatively low-cost biomarker that can be used in clinical practice.

译文

区分尿脓毒症和发热性尿路感染在治疗决策中很重要,以指示合适的治疗方法以避免脓毒症相关器官衰竭。准确的诊断是耗时的,并且容易受到假阳性结果的影响。此外,患者对尿脓毒症的反应复杂多样。因此,本研究旨在开发一种新的早期诊断预测因子,该预测因子可以结合初始降钙素原和白蛋白水平来区分尿脓毒症患者和发热性尿路感染患者。我们进行了一项回顾性研究,涉及从2013年1月到2017年12月的140例发热性尿路感染患者。进行单因素和多因素logistic分析,以确定区分尿脓毒症与发热性尿路感染的独立危险因素。进行受试者工作特征 (ROC) 曲线分析以比较降钙素原/白蛋白比值的预测准确性。尿脓毒症组患者的降钙素原/白蛋白比值高于热性尿路感染组 [2.254 (0.978、6.299) vs 0.021 (0.004、0.095); P  < .001]。基于多因素logistic分析,降钙素原/白蛋白比值 [调整比值比 (OR) 1.029,95% 置信区间 (CI) 1.013-1.045,p  < .001] 是尿脓毒症的独立预测因子,可与发热性尿路感染患者区分。降钙素原/白蛋白比值的ROC曲线下面积 (AUC) 为0.937 (95% CI,0.894-0.980); P  < .001。分别84.62% 和96.00% 降钙素原/白蛋白比值临界值 (>0.44) 的敏感性和特异性。此外,在65例尿毒症患者的亚组中,尿毒症休克组的降钙素原/白蛋白比值高于无尿毒症休克患者组 [5.46 (1.43,6.58) vs 1.24 (0.63,4.38); P   =  .009].我们的研究表明,降钙素原/白蛋白比值是一种早期诊断预测因子,可以区分尿脓毒症和发热性尿路感染。此外,在尿毒症患者中,降钙素原/白蛋白比值较高的患者更容易发生尿毒症休克。我们的发现表明,降钙素原/白蛋白比率是一种快速且相对低成本的生物标志物,可用于临床实践。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录